Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

23.66 +0.65 (+2.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,262,600
Open 22.92
Bid (Size) 23.64 (4)
Ask (Size) 23.66 (15)
Prev. Close 23.01
Today's Range 22.92 - 24.23
52wk Range 9.900 - 27.20
Shares Outstanding 9,587,155
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Proposed Underwritten Public Offering
From Viridian Therapeutics, Inc.
Via Business Wire

Performance

YTD
+19.7%
+19.7%
1 Month
+9.6%
+9.6%
3 Month
+35.0%
+35.0%
6 Month
+72.2%
+72.2%
1 Year
+6.7%
+6.7%

More News

Read More
Expert Outlook: Viridian Therapeutics Through The Eyes Of 6 Analysts
Via Benzinga
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results
Via Benzinga
Viridian (VRDN) Q2 Net Loss Widens 55%
Via The Motley Fool
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
From Viridian Therapeutics, Inc.
Via Business Wire
What 5 Analyst Ratings Have To Say About Viridian Therapeutics
Via Benzinga
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Viridian Therapeutics, Inc. - Common Stock publicly traded?
Yes, Viridian Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Viridian Therapeutics, Inc. - Common Stock trade on?
Viridian Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Viridian Therapeutics, Inc. - Common Stock?
The ticker symbol for Viridian Therapeutics, Inc. - Common Stock is VRDN on the Nasdaq Stock Market
What is the current price of Viridian Therapeutics, Inc. - Common Stock?
The current price of Viridian Therapeutics, Inc. - Common Stock is 23.66
When was Viridian Therapeutics, Inc. - Common Stock last traded?
The last trade of Viridian Therapeutics, Inc. - Common Stock was at 10/30/25 04:00 PM ET
What is the market capitalization of Viridian Therapeutics, Inc. - Common Stock?
The market capitalization of Viridian Therapeutics, Inc. - Common Stock is 226.83M
How many shares of Viridian Therapeutics, Inc. - Common Stock are outstanding?
Viridian Therapeutics, Inc. - Common Stock has 227M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.